The Art of Gene Therapy Digital Summit: EMEA 2021
MilliporeSigma invites you to the Art of Gene Therapy digital summit, a free five-session event drawing on the collective experience of industry leading gene therapy companies and regulatory agencies. The digital summit will shine a light on gene therapy future technologies, technical challenges, lessons learned from scale up to
commercialization and what is on the horizon for regulatory guidelines in addition to a specific focus on the vision for EMEA region specifically. Sign up for all days and have the option to watch the sessions relevant to you. Register today and be at the forefront of the future of gene therapy. This digital summit is co-hosted with PharmaIntelligence.
Day 1: Monday, May 3rd – The current state of Gene therapy and evolving purification strategies
15:00 – 15:05 Introduction/Opening remarks
Nargisse El Hajjami, Associate Director Cell & Gene Therapy Segment EMEA, MilliporeSigma / Paul Beckett, Technical Applications Consultant Downstream EMEA, MilliporeSigma
15:05 – 16:00 Gene therapy sector overview
Janet Lambert, CEO, Alliance for Regenerative Medicine (ARM)
16:00 – 17:00 Exploring new strategies to improve viral vectors purification processes
Christina Peixoto, Head of Downstream Process ACTU, iBET
Day 2: Wednesday, May 5 – The journey from scale up to commercialization
15:00 – 16:00 Yesterday’s learnings: Trial and errors from scale up to commercialization
Susan Abu-Absi, SVP, Pharmaceutical Development & Technology at bluebird bio
16:00 – 17:00 Bottlenecks in viral vector production
Hanna Leinonen, Senior Scientist Upstream, Kuopio Center for Gene and Cell Therapy, KCT / Igor Oruetxebarria, Senior Scientist Downstream, Kuopio Center for Gene and Cell Therapy, KCT
Day 3: Monday, May 10 – The future of gene therapy FDA guidelines and analytical development
15:00 – 16:00 Regulatory horizons: 2020 vision on FDA guidelines
Peter Marks, Director of CEBR at FDA
16:00 – 17:00 Tomorrows view: What’s next for analytical development?
Alison Armstrong, Global Head Field Technology Management, Services R&D MilliporeSigma
Day 4: Wednesday, May 12 – Promising technologies of tomorrow and futuristic process design
15:00 – 16:00 Futuristic outlook on gene therapy
Patrick Sullivan, Head of Gene Editing and Novel Modalities R&D MilliporeSigma
16:00 – 17:00 A-Gene: Applying Quality By Design principles to the development and manufacture of gene therapies
Michael Lehmicke, Director of Science and Industry Affairs at ARM
Day 5: Monday, May 17 – The next decade of gene therapy in the EMEA region
15:00 – 15:30 Establishing the era of gene therapy in emerging countries – Science and strategy: A case study Shaheer Bardissi, Executive board member, Gene & cell therapy and Immuno-oncology, Minapharm Pharmaceuticals
15:30 – 16:00 Improving access to gene therapies – Focus on EMEA
Lorenzo Montrasio, Human Rights Directorate of the Council of Europe
16:00 – 17:00 The next decade of gene therapy in EMEA: Q&A panel discussion
Ranjeet Patil, Segment Head, Cell and Gene Therapy, MilliporeSigma
Lorenzo Montrasio, Human Rights Directorate of the Council of Europe
Jim McNally’s, Chief Scientific Officer, BioAgilytix
Mazen Hassanain, Managing Director SaudiVax – KSA
Anthony Shillings, Head of Downstream Proceed Development Cell and Gene Therapy, GSK – UK
- Navigating The Regulatory Maze: Fundamentals for Drug Development - May 25, 2022
- An Introduction to the Biopharmaceutical Industry - April 8, 2022
- How to Accelerate and Enhance ADC Therapies - April 13, 2022